Table 1 Baseline characteristics of the subjects according to underlying malignancy
RCC (N = 93) | Non-RCC (N = 17) | |
|---|---|---|
Male sex , no. (%) | 77 (82%) | 10 (63%) |
Age (years) | 59 (52, 67) | 54 (48, 59) |
BMI (kg/m2) | 23.5 (20.0, 25.2) | 23.8 (21.4, 25.3) |
Diabetes mellitus (%) | 17 (18%) | 0 (0%) |
Hypertension (%) | 33 (36%) | 2 (11%) |
ACE inhibitor/ARB (%) | 15 (16%) | 1 (6%) |
Diuretics (%) | 40 (43%) | 5 (29%) |
Previous TKI Treatment (%) | 93 (100%) | 9 (53%) |
Radical nephrectomy | 74 (80%) | 0 (0%) |
Creatinine (mg/dL) | 1.19 (1.01, 1.43) | 0.78 (0.64, 0.86) |
eGFR (mL/min/1.73 m2) | 63 (51, 76) | 104 (94, 132) |
>90 | 10 (11%) | 14 (82%) |
60–90 | 41 (44%) | 2 (12%) |
30–60 | 40 (43%) | 1 (6%) |
15–30 | 2 (2%) | 0 (0%) |
Proteinuria (%) | 25 (28.1%) | 0 (0%) |
Everolimus | ||
Total dose (mg) | 1155 (670, 1900) | 790 (332, 1825) |
Duration (weeks) | 20 (12, 36) | 12 (6, 26) |